EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Small‐Molecule KRAS Inhibitors by Tyrosine Covalent Bond Formation

Alexander D Landgraf, Robert Brenner, Mona K Ghozayel, Khuchtumur Bum-Erdene, Giovanni Gonzalez-Gutierrez, Samy O Meroueh iD

ChemMedChem · 2025

DOI: 10.1002/cmdc.202400624 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemMedChem, 2025. Verfasst von Alexander D Landgraf und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN, 46202, USA. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins p21(ras), Small Molecule Libraries, Tyrosine, Protein Kinase Inhibitors. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NHLBI NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The development of the KRAS G12C inhibitor sotorasib is a major advance toward drugging KRAS. However, the G12C mutation is only found in about 10% of KRAS‐driven tumors. KRAS possesses several tyrosine amino acids that could provide alternative sites for covalent drug development. Here, a library of aryl sulfonyl fluorides identified 1 (SOF‐436) as an inhibitor of KRAS nucleotide exchange by guanine exchange factor SOS 1 and KRAS binding to effector protein rapidly accelerated fibrosarcoma kinase (RAF). Tyr‐64 is the major reaction site of 1 (SOF‐436), although minor reaction at Tyr‐71 is also observed. The fragment binds to the Switch II pocket of KRAS based on whole protein mass spectrometry, nucleotide exchange, effector protein binding, and nuclear magnetic resonance studies. Cocrystal structures of smaller fragments covalently bound to KRAS at Tyr‐71 provide a strategy for the development of Switch I/II KRAS covalent inhibitors. A bioluminescent resonance energy transfer (NanoBRET) assay reveals that the compounds inhibit KRAS binding to RAF in mammalian cells. Although not yet suitable as chemical probes, these fragments provide starting points to develop small molecules to investigate tyrosine as a nucleophile for covalent inhibition of KRAS in tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins p21(ras)Small Molecule LibrariesTyrosineProtein Kinase InhibitorsHumansStructure-Activity RelationshipMolecular StructureDose-Response Relationship, Drug

Stichwörter der Autor:innen

KRAScovalent inhibitorsguanine exchange factorsprotein–protein interactionstyrosines

Substanzen

Proto-Oncogene Proteins p21(ras)KRAS protein, humanSmall Molecule LibrariesTyrosineProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN, 46202, USA.
  • Department of Biochemistry, University of Illinois Urbana-Champaign, Urbana, IL, 81601, USA.
  • Cancer Center at Illinois, University of Illinois Urbana-Champaign, Urbana, IL, 81601, USA.
  • Department of Molecular and Cellular Biochemistry, Indiana University, Bloomington, IN, 47405, USA.

ORCID-Profile: Samy O Meroueh

Förderung

  • NCI NIH HHS
  • NHLBI NIH HHS
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Landgraf, A. D., Brenner, R., Ghozayel, M. K., Bum-Erdene, K., Gonzalez-Gutierrez, G., & Meroueh, S. O. (2025). Small‐Molecule KRAS Inhibitors by Tyrosine Covalent Bond Formation. ChemMedChem. https://doi.org/10.1002/cmdc.202400624

Vancouver

Landgraf AD, Brenner R, Ghozayel MK, Bum-Erdene K, Gonzalez-Gutierrez G, Meroueh SO. Small‐Molecule KRAS Inhibitors by Tyrosine Covalent Bond Formation. ChemMedChem. 2025. doi:10.1002/cmdc.202400624

BibTeX
@article{Landgraf2025,
  author = {Landgraf, Alexander D and Brenner, Robert and Ghozayel, Mona K and Bum-Erdene, Khuchtumur and Gonzalez-Gutierrez, Giovanni and Meroueh, Samy O},
  title = {Small‐Molecule KRAS Inhibitors by Tyrosine Covalent Bond Formation},
  journal = {ChemMedChem},
  year = {2025},
  doi = {10.1002/cmdc.202400624}
}
Kostenlos starten →